0001209191-18-047483.txt : 20180817
0001209191-18-047483.hdr.sgml : 20180817
20180817172642
ACCESSION NUMBER: 0001209191-18-047483
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180815
FILED AS OF DATE: 20180817
DATE AS OF CHANGE: 20180817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lombardo Ilise
CENTRAL INDEX KEY: 0001750158
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 181026616
MAIL ADDRESS:
STREET 1: C/O AXOVANT SCIENCES, INC.
STREET 2: 11 TIMES SQUARE, 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Sciences Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-15
0
0001636050
Axovant Sciences Ltd.
AXON
0001750158
Lombardo Ilise
C/O AXOVANT SCIENCES, INC.
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
2.02
2018-08-15
4
A
0
100000
0.00
A
2028-08-14
Common Shares
100000
100000
D
One-third of the option will vest at such time as the Issuer's stock price is equal to $6.06; one-third of the option will vest at such time as the Issuer's stock price is equal to $10.10; and one-third of the option will vest at such time as the Issuer's stock price is equal to $14.14, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date.
The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
/s/ Alison Haggerty, Attorney-in-Fact
2018-08-17